← SynDRA

TIVOZANIB

SynDRA canonical compound SYN0024931 — structure-anchored drug synonym record

All known targets

• FLT4
• FLT1
• KDR
• PDGFRB
• KIT
• PDGFRA
• FRK
• RIPK3
• RIPK2
• RET
• PTK6
• PEBP1

Mechanisms of action (all sources)

• VEGFR inhibitor
• FLT1 INHIBITOR
• Vascular endothelial growth factor receptor inhibitor
• FLT4 INHIBITOR
• KDR INHIBITOR
• KIT INHIBITOR
• Stem cell growth factor receptor inhibitor
• PDGFRB INHIBITOR
• Platelet-derived growth factor receptor beta inhibitor
• FLT4 MODULATOR
• KDR MODULATOR

Drug classes

• Tyrosine Kinase Inhibitors
• Enzyme Inhibitors
• Protein Kinase Inhibitors
• Kinase Inhibitor

ATC classes

• L01E · PROTEIN KINASE INHIBITORS

Cross-references

• PubChem CID: 9911830
• ChEMBL: CHEMBL1289494
• DrugBank: DB11800
• ChEBI: 91327
• KEGG: D09683
• RxNorm: 2534233
• PDB: AV9
• Wikipedia: Tivozanib
• TTD: D0W7JZ
• LINCS BRD: BRD-K53414658

Synonyms

• tivozanib hydrochloride monohydrate
• fotivda
• Kil8951
• AV-951
• KRN951
• KRN-951
• ASP-4130
• DC-001164TIVOZANIBAV9511-(2-CHLORO-4((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-3-(5-METHYLISOXAZO-3-YL)UREA
• Fotivda
• Kil-8951
• KIL8951
• OPHTHOTECH
• TIVOZANIB (AV-951)
• TIVOZANIB (OPHTHALMIC)
• TIVOZANIB HCL
• ASP4130/AV-951
• AV 951
• Tivozanib (AV-951)
• KRN 951
• AV951
• 1-(2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-3-(5-methylisoxazol-3-yl)urea
• N-[2-CHLORO-4-[(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA
• CHEMBL1289494
• AV-951;KRN951
• 1-(2-CHLORO-4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY)PHENYL)-3-(5-METHYLISOXAZOL-3-YL)UREA
• 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea
• 172030934T
• 1-(2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)-oxy)phenyl)-3-(5-methylisoxazol-3-yl)urea
• 1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea
• N-(2-Chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea
• Urea, N-(2-chloro-4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)-
• Tivozanib [USAN]
• Tivozanib [USAN:INN]
• 4ase
• N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea
• AV9
• UNII-172030934T
• AV-951,Tivozanib

Reported adverse events

• Fatigue
• Hypertension
• Hypothyroidism
• Rash
• Stomatitis
• Amylase increased
• Back pain
• Cough
• Lipase increased
• Nausea
• Proteinuria
• Vomiting